Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

Phase 4

Completed

• Conditions: Healthy
• Interventions: Drug: Efavirenz, tenofovir disoproxil fumarate and emtricitabine

• Registration Number: NCT03309566
• Lead Sponsor: Laboratorio Elea Phoenix S.A.

Brief Summary

Bioequivalence study of two formulations containing a fixed dose combination of 600 mg Efavirenz, 200 mg Emtricitabine and 300 mg Tenofovir Disproxyl Fumarate in coated tablets under a single-dose, two-way crossover design.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-09-04
• Primary Completion: 2017-02-28
• Study Completion: 2017-02-28
• Status Verified: 2017-10
• Study First Submitted: 2017-10-10
• Study First Submitted QC: 2017-10-12
• Last Update Submitted: 2017-10-12
• Study First Posted: 2017-10-13
• Last Update Posted: 2017-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Male subjects between 18 and 55 years. Subjects with body mass index (BMI) between 19 and 27 kg / m². Subjects whose complementary tests (ECG, blood and urine) are within normal and / or clinically insignificant according to the judgment of the investigator.

Subjects with systolic blood pressure between 110 mmHg and 139 mmHg; diastolic pressure between 70 mmHg and 89 mmHg; heart rate between 50 and 90 beats per minute.

Subjects who signed informed consent.

Read More

Exclusion Criteria

Background of clinically significant allergies (except untreated asymptomatic seasonal allergies), drug hypersensitivity and / or hypersensitivity to any component of the formulations studied.

Drop of more than 20 mmHg in systolic blood pressure or more than 10 mmHg diastolic pressure in the first 3 minutes of postural change.

Active smoker more than 10 cigarettes / day. Pregnant or lactating women. Current clinical evidence of severe digestive disorders, surgery of the digestive tract (except appendectomy).

Current clinical evidence of kidney disease. Current evidence of liver disorders Current clinical evidence of respiratory and heart diseases. The presence of diabetes mellitus, thyroid dysfunction or other endocrine disorder.

Evidence of gastroduodenal disease. Current presence of any malignancy. History of abuse or addiction to drugs or alcohol during the past three years. Participation in a clinical trial within the last three months. Use of any drug within fourteen days before the start of the study. Subject donated or suffered blood loss during the last twelve weeks before the start of the study, or intends to donate blood within three months of the completion of the study.

Excessive drinking of tea, cocoa, mate, coffee and / or beverages containing caffeine (> 5 cups / day) or wine (> 0.5 L / day) or alcohol (> 50 ml / day).

ECG abnormalities. Positive serology for HIV, hepatitis B or hepatitis C.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Test - Reference	Efavirenz, tenofovir disoproxil fumarate and emtricitabine	A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
Reference - Test	Efavirenz, tenofovir disoproxil fumarate and emtricitabine	A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).

Primary Outcome Measures

Name	Time	Method
Cmax	192 hours	Maximum plasma concentration
AUC	192 hours	Area under the curve

Secondary Outcome Measures

Name	Time	Method
Adverse events	192 hours	Drug related toxicity

Trial Locations

Locations (1)

DominguezLab; 🇦🇷 Paraná, Entre Ríos, Argentina